Poster presentationsBI18 The management of vulval intraepithelial neoplasia in immunosuppressed women: outcome and recommendations from a multidisciplinary vulval clinic
Radhika Bali,Jenny Chung,Caroline English,Jacqueline McDermott,Helen Staley,Sapna Harish,Charlotte Cohen,Elaine Palmer,Claire Fuller,John Butler,Randa Akel
DOI: https://doi.org/10.1093/bjd/ljae090.306
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract Vulval intraepithelial neoplasia (VIN) is a premalignant change of the vulval epithelium that can progress to squamous cell carcinoma (SCC). Immunosuppressed patients are a high-risk subset, with a greater risk of recurrence with standard treatment. To date, there is limited research focusing on this vulnerable population. A retrospective study was designed to review the treatment outcomes of immunosuppressed patients with VIN in a tertiary, multidisciplinary vulval service. In total, 104 biopsy-proven adults with VIN were identified from a histological database from 1 April 2013 to 31 March 2023. Patient demographic data, disease type and treatment outcome were collected. Electronic records and medical photography, where available, were used to retrospectively map each vulval lesion in quadrants. Complete response (CR) was defined as being clinically and/or pathologically clear of disease at 3 months’ follow-up. Recurrence was defined as lesions reappearing in the same quadrant after achieving CR. Data analyses were performed using IBM SPSS Statistics for univariate analyses. Overall, 31 of 104 patients (30%) were immunosuppressed, developing 47 lesions in the study period. This was due to HIV (n = 9), diabetes (n = 5), active malignancy (n = 10) and other causes (n = 7). The mean age was 54 years (range 20–94) with a mean follow-up duration of 70 months (range 11–132). The histological subtypes of VIN included low-grade squamous intraepithelial lesion (11%), high-grade squamous intraepithelial lesion (72.3%), differentiated VIN (4.3%) and microinvasive SCC (14.9%). Immunosuppressed patients were more likely to have multifocal disease (57.4% vs. 29.8%, P = 0.003) with previous human papillomavirus (HPV) burden (66.7% vs. 36.6%, P = 0.008). For those screened during the study period, immunosuppressed patients were more likely to have associated anal intraepithelial neoplasia (25.8% vs. 6.9%, P = 0.02) and cervical intraepithelial neoplasia (29.0% vs. 15.2%, P = 0.031). The CR rate from first-line treatment (imiquimod, surgery, laser or PlasmaJet®) was 54.8% in the immunosuppressed cohort compared with 75.6% in the control group (P = 0.073). There was no difference in the rate of recurrence or progression to SCC. There was no death due to disease observed in the immunosuppressed group, compared with three patients in the control group. In summary, our high-risk population with VIN was found to have a higher burden of HPV and was more likely to have multicentric disease. The treatment outcome was noninferior to the control group’s, unlike similar previous case series. This highlights the need for multidisciplinary clinics offering long-term close monitoring, with early treatment and HPV surveillance.
dermatology